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Abstract 
 
Introduction: Systemic lupus erythematosus (SLE) is a multi-system autoimmune 
disease. There are three drugs licensed for the treatment of lupus: corticosteroids, 
hydroxychloroquine and belimumab. Immunosuppressants such as azathioprine, 
methotrexate and mycophenolate are also used. Despite these treatments there is 
still considerable morbidity. New treatments are needed for the management of 
active lupus. Epratuzumab a humanized IgG1 monoclonal antibody that targets 
CD22 resulting in selective B cell modulation that has been considered a potential 
treatment for SLE.  
 
Areas covered: Summary of the relevant pathogenesis and disease activity 
measurements used in SLE patients, current treatments and unmet needs in SLE, 
pharmacokinetics and pharmacodynamics of epratuzumab therapy, and a summary 
of the 7 clinical trials that have investigated the efficacy and safety of epratuzumab in 
SLE.  
 
Expert commentary: It is not clear why trials have failed to demonstrate efficacy but 
high placebo response rates from optimisation of standard of care and a sub-optimal 
dosing regimen may have played a role. Post-hoc analysis suggested that there may 
be subgroups that did respond, such as anti-SSA positive patients with features of 
Sjogren’s syndrome. Further research is needed to explore this and other potential 
sub-groups that might respond. 
 
Keywords: B cell modulation, BILAG, BICLA, CD22, disease activity, epratuzumab, 
monoclonal antibody, lupus, outcome, response, Sjogren’s syndrome, SLEDAI-2K, 
treatment  
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Epratuzumab for the treatment of Systemic Lupus Erythematosus 
 
1. Search criteria  
 
MEDLINE and PubMed databases where searched using the keywords 
epratuzumab, systemic lupus erythematosus (SLE) and CD22. All clinical papers 
were selected and included in this review. For mechanistic papers recent up to date 
review articles were selected along with a few of the principle original papers.  
 
2. Introduction  
 
Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease.  
The estimated incidence and prevalence of SLE in the UK is 4.91/ 100,000 and 
97.03/100,000 respectively (1) and in the USA 5.5/100,000 and 72.8/100,00 
respectively (2). SLE is more common in females than in males with a ratio of 8-15:1 
and tends to present between the second and fifth decades (2). SLE is most 
prevalent in people of African, South Asian and Chinese descent (1,3).  
 
SLE is a clinical diagnosis that should be associated with at least one serological 
abnormality that supports an underlying autoimmune immune-complex mediated 
pathological process (4). The Systemic Lupus International Collaborating Clinics 
(SLICC) classification criteria can be used as a validated objective classification tool 
in research and clinical practice (5). The American College of Rheumatology 
classification criteria for SLE has been used for longer in lupus research, contains 
less items and is less sensitive but is a bit more specific (4). 
 
2.1  Pathogenesis of SLE 
 
There are numerous genetic and environmental factors associated with the 
development of lupus (6-8). SLE is thought to be primarily a B-cell mediated disease. 
Inappropriate immune activation leads to the expansion of autoreactive B cells that 
develop into plasma cells producing many autoantibodies including anti-DNA, anti-
Ro, and antiphospholipid antibodies. Defective immune clearance of apoptotic cells 
leading to exposure of intra-cellular antigens to the immune system, complement 
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deficiency (C1q, C2, C4) (9) and mannose binding lectin (MBL) deficiency (10). 
Autoantibodies causing immune complex disease trigger complement activation and 
inflammatory cytokine release leading to the inflammatory features of SLE (11,12).  
The autoreactive B cells also have a role in activating antigen presenting cells 
(APCs), producing inflammatory cytokines and regulating T cell activation and 
expansion (6).  
 
2.2  Measuring disease activity in SLE 
 
SLE is a heterogeneous disease affecting one or multiple organ systems. Three 
patterns of disease have been reported: acute disease flare, more chronic active 
disease and quiescence (13). Clinical assessment of disease activity may be 
confounded by chronic organ damage from SLE, co-morbidities such as fibromyalgia 
and adverse drug reactions (4). Disease activity indices have been developed for 
use in clinical trials and observational studies (14).  
 
The British Isles Lupus Assessment Group Disease Activity (BILAG) index (15) and 
its revision the BILAG-2004 index (16,17) record disease activity in the last 4 weeks. 
The scoring is based on an intention to treat principle derived by consensus. Disease 
activity in each system is attributed a letter (categorical score) corresponding to the 
level of disease activity. Score A is assigned to severe disease activity requiring 
increases in prednisone to >20 mg daily and/or addition of immunosuppressive 
agents. Score B is assigned to less active disease needing only low dose 
prednisolone and/or symptomatic treatment with non-steroidal anti-inflammatory 
drugs or antimalarials. Score C is assigned to mild or improving features requiring 
only symptomatic therapy. Score D is assigned to previous disease activity in a 
system with no current disease activity. Score E indicates no prior or current disease 
activity in the system. The BILAG-2004 revision used similar scoring principles as 
the original BILAG index but changed the grading of severe disease activity items if 
they were improving (14). There were 8 systems in the original BILAG index (15); 
constitutional, mucocutaneous, neurological, musculoskeletal, 
cardiovascular/respiratory, vasculitis, renal and haematological. In the BILAG-2004 
index the vasculitic features were moved into individual organ systems and 
gastrointestinal and ophthalmologic systems were added resulting in a total of 9 
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systems. Many of the items in each system, their glossary definitions and the option 
for numerical scoring were updated in this revision (16,17). The classic BILAG and 
BILAG-2004 indices are summarised in table 1. 
 
The SLE Disease Activity Index 2000 (SLEDAI-2K) is another validated global 
measure of SLE disease activity (18). It provides a weighted score for each of 24 
clinical, haematological and serological items originally over a recall period of 10 
days but was more recently validated to be used over 4 weeks to give a numerical 
score indicating overall disease activity (14). The components and scoring of 
SLEDAI-2K are summarised in table 1. The physician’s global assessment (PGA) is 
used in composite responder indices. The PGA score is determined by the overall 
disease activity score given by the assessing doctor using a visual analogue scale  
(14). More recent studies have used the composite BILAG-based combined lupus 
assessment (BICLA). It was developed by an expert panel and combines the BILAG-
2004 index, SLEDAI-2K and PGA (14). A BICLA responder is defined as a patient 
meeting predefined criteria for BILAG-2004 index improvement with no worsening of 
total SLEDAI-2K score or PGA and no treatment failure. This is similar to the SLE 
responder index (SRI) used in the belimumab trials (19,20) which requires 
improvement in the SELENA version of SLEDAI (4), with no significant worsening in 
the BILAG index and no worsening in the PGA (14). The BICLA and original SRI are 
summarised in table 2. 
 
2.3  Current therapeutic approaches and unmet needs 
 
The current licensed pharmacological treatments for SLE are; hydroxychloroquine, 
corticosteroids and belimumab (4). Immunosuppressants such as azathioprine, 
methotrexate, mycophenolate mofetil, ciclosporin, tacrolimus and cyclophosphamide 
are used (4). Belimumab is the only biological therapy to be licensed following 2 
successful phase III trials (19,20). Rituximab has shown efficacy in open label 
studies and is used in refractory lupus despite failing in phase 3 clinical trials (4).  
 
Despite significant advances in care with standard therapy a significant number of 
patients have flares or chronic moderate activity that are treated with corticosteroids 
and immunosuppressants that contribute to end organ damage and risk of infection, 
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atherosclerosis and premature death. There is plenty of scope for the development 
of more targeted and effective therapies. 
 
2.4  CD22 
 
CD22 is a 135-kD type I transmembrane sialoglyco-protein of the Ig superfamily 
found specifically on B cells (21). CD22 is thought to play an important role in the 
modulation of B cells and humoral immunity. CD22 acts as an inhibitory co-receptor 
to the B-cell receptor (BCR) causing BCR induced cell death (21). When CD22 and 
BCR are cross-linked by antigen triggers, CD22 undergoes phosphorylation causing 
downstream reduction of BCR calcium signalling (22) and down regulation of BCR 
signalling ultimately resulting in BCR induced cell death and reduced overall survival 
of B transformed cells or diminished proliferation of B cells from patients with SLE 
(21,23). Studies of CD22 deficient mice show increased BCR calcium signalling 
response to BCR ligation, implying that CD22 inhibits BCR signalling by reducing 
calcium efflux (24) possibly via potentiating plasma membrane calcium-ATPase 
activity (25). Because of the B cell specificity of CD22 and the inhibitory effects of 
stimulating CD22, it has been considered a prime therapeutic target in B cell 
mediated autoimmunity such as SLE as well as for non-Hodgkin’s lymphoma (26).  
 
3. Epratuzumab structure and chemistry 
 
Epratuzumab is a humanized CD22 targeted IgG1 monoclonal antibody derived from 
the murine IG2a monoclonal antibody LL2, which binds to extracellular domain of 
CD22 (27). Epratuzumab has low immunogenicity as only 5-10% of the molecule 
consists of murine sequence the rest being human (28). Like many monoclonal 
antibodies it was first developed as a treatment for lymphoma (27). Epratuzumab is 
given as an IV infusion typically with an infusion time between 30 – 60 minutes. 
Immunomedics Inc. developed epratuzumab originally for use in oncology (26,27)  
and licensed Union Chimique Belge (UCB) to develop epratuzumab for use in 
autoimmune diseases such as SLE. 
 
3.1  Epratuzumab pharmacodynamics  
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Epratuzumab is thought to work primarily via the immunomodulation of B cells via its 
action on CD22 and subsequent effects on BCR signalling, surface receptor 
expression, cytokine expression, potential reduction in plasma cell generation as well 
as effects on cell adhesion and migration as discussed below (22,28-33). The main 
mechanisms of action are summarised in figure 1.  
  
Epratuzumab activates the regulatory functions of CD22 by initiating CD22 
phosphorylation (28). It induces the internalisation of CD22 and of CD79α, which is a 
part of the BCR complex (22), hence disrupting BCR signalling. Epratuzumab down 
regulates CD19, CD79β and CD21 from the cell surface via trogocytosis (29). 
Trogocytosis is the process by which cell surface receptors are transfer from one cell 
to another, in this case to phagocytic cells such as macrophages. CD19 has been 
implicated in the pathogenesis of SLE with certain polymorphisms associated with 
the predisposition to SLE (34). CD19 loss increases the BCR threshold and further 
reduces BCR signalling (35).  
 
Epratuzumab inhibits the production of the pro-inflammatory cytokines TNF and IL-6 
whilst preserving production of the anti-inflammatory cytokine IL-10 (30,36). 
Therefore epratuzumab should change the overall balance of pro- versus anti-
inflammatory cytokines. 
 
Another effect of epratuzumab is to alter the B cell migratory capacity by modulating 
cell adhesion molecules. Epratuzumab has been shown to down regulate CD62L 
and β7 integrin whilst up regulating β1 integrin and increasing B cell migration to 
CXCL12 (31). CD62L and β7 integrin are adhesion molecules used for lymphocyte 
recruitment to inflamed tissues and mucosa respectively. By down regulating these 
molecules pathological B cells may be impeded in their recruitment to sites of 
inflammation. CXCL12 is a chemokine produced by bone marrow and along with β1 
integrin are used in the recruitment of lymphocytes into the bone marrow (32). One 
effect of this up regulation could be that naïve B cells become trapped in the bone 
marrow preventing them from fully differentiating in secondary lymphoid organs.  
 
In contrast to Rituximab in vitro studies into the mechanism of epratuzumab show no 
complement dependent cytotoxicity (CDC) and very small antibody dependent 
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cellular cytotoxicity (ADCC) (37). Interestingly data from 2 phase III clinical trials 
(EMBODY 1 and EMBODY 2, see below) show a total B cell reduction of 30-40% 
with epratuzumab (33). This can be explained by the fact that B-cells require BCR 
activation for maturation and survival (38). Therefore with epratuzumab reducing 
BCR signalling via CD19, CD79β/ CD79α and CD21 internalisation/ trogocytosis and 
CD22 phosphorylation less B cells mature and survive causing a reduction in overall 
B cell numbers. In particular it is the CD27negative B cell subset that is most 
depleted due to the fact that CD22 is more highly expressed in this subset (31). 
 
In summary epratuzumab works by a process of immunomodulation of B cells by 
enhancing the normal inhibitory function of CD22 on the BCR (39) with less than 
50% B cell depletion, as opposed to ADC and ADCC associated with rituximab 
which targets CD20 and causes marked B cell depletion. The advantages of 
epratuzumab over a B cell depleting drug such as rituximab could be disease 
amelioration without potentially dangerous immunosuppressive effects. For example 
rituximab has been linked with progressive multifocal leukoencephalopathy (PML), a 
fatal infection of the central nervous due to JC virus (40), although this remains a 
rare complication and occurs with other monoclonal antibodies and cytotoxic agents 
(41).  
 
3.2  Epratuzumab pharmacokinetics 
 
Pharmacokinetic results from the original non-Hodgkin’s lymphoma trials suggested 
that the serum half-life of epratuzumab is around 23 days, similar to the half-life of 
human IgG (26,42). In the initial clinical trial of epratuzumab in SLE serum 
concentrations of epratuzumab were measured up to week 18 (12 weeks post last 
infusion). Concentrations fell with time since the last infusion but were measurable in 
all patients at 10 weeks (4 weeks post last infusion) and continued to be detected in 
some patients at 18 weeks (12 weeks post last infusion) (43).  
 
4. Clinical efficacy  
 
To date there have been 7 clinical trials (1 phase IIa open label trial, 1 phase I/II, 3 
phase IIb and 2 phase III randomised controlled trials (RCTs)) and 3 extended open 
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label studies (results of ALLEVIATE and EMBLEM extensions are published, 
EMBODY extension unpublished (ClinicalTrials.gov Identifier: NCT01408576)) 
looking at the efficacy, safety and pharmacokinetics of epratuzumab in SLE. In total 
2167 patients were recruited into these trials with a total of 1313 patients receiving 
epratuzumab as part of a RCT and 57 patients receiving epratuzumab as part of an 
open label trial (14 patients received epratuzumab in the initial open label trial and 43 
patients switched from placebo to epratuzumab in an open label extension). The 
primary endpoint in all trials (with the exception of the Japanese phase I/II study) has 
involved reduction in SLE disease activity defined either a BILAG or BICLA index 
responder as described earlier and in tables 1 and 2. All studies have also looked at 
drug safety outcomes.  
 
 
4.1 Initial open label trial (43)    
 
The initial open label, non-randomised, single centre clinical trial of epratuzumab 
was conducted with 14 patients with the aim of obtaining preliminary evidence of its 
therapeutic effect and drug safety in SLE. Study outcomes were BILAG score before 
and after treatment, adverse events and serological measurements. Inclusion and 
exclusion criteria are summarised in table 3 and the results in table 4. In total 14 
patients were entered; all of Caucasian ethnicity (13 females and 1 male) with an 
age range 23-53 years old (median age 40).  All patients had a BILAG score of 
between 6-12 (median 10 using the original ad-hoc numerical score (44)). Patients 
received 4 doses of 360 mg/m2 at 2 weekly intervals. Epratuzumab was 
administered along with paracetamol and an antihistamine as premedication. 
Patients were followed up at 6, 10, 18 and 32 weeks. Intravenous (IV), intramuscular 
(IM), intra-articular (IA) and high dose corticosteroids along with cyclophosphamide 
were not allowed within 4 weeks of study entry. Low dose background therapy was 
allowed as long as there were no dose adjustments within 4 weeks of study entry.  
 
The majority of patients completed the trial with 12 of 14 patients receiving all 4 
infusions. Statistically significant improvements in BILAG scores were observed with 
77%, 71% and 38% of patients showing a 50% or more improvement in classic 
BILAG score at 6, 10 and 18 weeks respectively. All BILAG organ systems showed 
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some disease activity improvement in response to epratuzumab apart from 
hematologic where 2 patients showed worsening of disease activity and no patients 
showing improvement. At week 18 only 3 patients (21%) had BILAG deterioration in 
at least one organ system.   
 
Adverse events (AEs) were reported in 10 patients; 6 had mild, short lasting infusion 
reactions such as sleepiness, flu like symptoms, tracheitis, arthralgia, myalgia, fever, 
nausea, headache and rash. Five patients developed infections such as otitis media, 
tonsillitis, cystitis, vaginal candidiasis and herpes zoster, that all resolved with 
appropriate treatment. There was one serious adverse event (SAE), which was 
thought to be unrelated to the drug and no deaths. Mean B cells were reduced by 
35% post epratuzumab and this decrease was consistent at 32 weeks. There was no 
consistent effect on immunoglobulins, T cells, autoantibodies or C3 levels. There 
were no anti-human epratuzumab antibodies detected.  
 
The limitations of this study were its small numbers, no control group or 
randomisation and no measurement of Health Related Quality of Life (HRQoL) or 
steroid sparing effects of epratuzumab. In conclusion this open label non-
randomised study demonstrated that epratuzumab is a generally safe and well 
tolerated drug with some possible disease ameliorating effects in SLE. 
 
 
4.2 Phase IIb trials: ALLEVIATE-1 and ALLEVIATE-2  (45,46)    
 
ALLEVIATE-1 and ALLEVIATE-2 were 2 phase IIb multicentre, multinational, double 
blinded, placebo-controlled, randomised controlled trials, looking at the efficacy and 
safety of epratuzumab in SLE. Unfortunately due to drug supply shortages the trials 
were discontinued early and the data were combined for analysis. ALLEVIATE-1 and 
ALLEVIATE-2 studied patients with at least 1 BILAG A organ system and at least 2 
BILAG B organ systems at baseline respectively.  
 
Inclusion and exclusion criteria are summarised in table 3 and the results in table 4. 
In ALLEVIATE-1 patients had to have BILAG A disease ≥1 organ systems (excluding 
10 
 
renal and CNS). In ALLEVIATE-2 patients had to have BILAG B activity ≥2 organ 
systems.  
 
In ALLEVIATE-1 patients were randomised to individualised standard of care (SOC) 
plus either epratuzumab 360mg/m2 or epratuzumab 720mg/m2 or placebo in a 1:1:1 
ratio. In ALLEVIATE-2 patients were randomised to individualised SOC plus 
epratuzumab 360mg/m2 or placebo in a 1:1 ratio. Assessments of disease severity 
using BILAG score were carried out every 4 weeks and were centrally graded by an 
independent blinded assessor. Patients were allowed to take background 
corticosteroids and immunosuppressants. If a disease flare occurred a protocol-
driven corticosteroid regime was followed.  
 
The primary end point was revised before the analysis was done and required 
BILAG response with no treatment failure at week 12 in the combined treatment 
groups from the two original trials. BILAG response was defined as all BILAG A 
scores reducing to B or lower and all BILAG B scores reducing to C or lower with no 
new BILAG A and less than 2 new BILAG B scores in other systems. Treatment 
failure was defined as new or increased use of oral corticosteroids or other 
immunosuppressants above baseline. Secondary endpoints were BILAG response 
at 24 and 36 weeks, time to initial BILAG response and total BILAG score at 12, 24 
and 48 and time to first sustained BILAG response, physician global assessment 
(PGA), patient global assessment (PtGA) and health related quality of life (HRQoL) 
measured with short form 36 survey (SF-36). Safety endpoints and immunological 
endpoint were also analysed.  
 
In total 90 patients were enrolled and randomised (36 in ALLEVIATE-1 and 54 in 
ALLEVIATE-2), with 37, 42 and 11 patients randomised to the placebo, epratuzumab 
360mg/m2 and epratuzumab 720mg/m2 groups respectively. Baseline characteristics 
were generally comparable between groups with exception of some expected 
difference in the epratuzumab 720mg/m2 group. This group had higher disease 
activity and higher background steroid use due to higher disease activity in patients 
in the ALLEVIATE-1 trial. 
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Due to premature discontinuation of the study a large number of patients did not 
complete the study as planned. In total 80% of patients in all groups were assessed 
at week 12 and over 60% were assessed at week 24.  
 
The study failed to meet its primary outcome with there being no significant 
difference in BILAG response at week 12. Of the 74 patients who received 12 weeks 
of treatment 44.1%, 20.0% and 30.3% of patients were BILAG responders in the 
360mg/m2, 720mg/m2 and placebo groups respectively (p=0.177 epratuzumab 
versus placebo) (45).  
 
Of the secondary outcomes there was no significant difference in BILAG response at 
24 and 36 weeks. There was no statistically significant difference in medium time to 
first initial BILAG response between the groups. Of exploratory outcomes, at 48 
weeks median BILAG scores decreased from 12 to 4, 15 to 6 and 12 to 7.5 from 
baseline in the 360mg/m2, 720mg/m2 and placebo groups respectively. The overall 
change from baseline in total BILAG score at week 48 for all epratuzumab patients 
vs placebo was significant (p=0.028) (45). 
 
The combined analysis showed a significant corticosteroid sparing effect of 
epratuzumab after post hoc adjustments for ethnicity, baseline immunosuppression 
and flare regime. At week 24 overall corticosteroid doses per patient were lower in 
both epratuzumab groups compared to placebo, seeing a reduction of 1051 mg 
(p=0.03 versus placebo) and 1973 mg (p=0.08 versus placebo) compared to placebo 
in the 360mg/m2 and 720mg/m2 groups respectively (46).  
 
The number of patients who had an improvement in physician global assessment 
(PGA) and patient global assessment (PtGA) was generally higher in the 
epratuzumab groups compared to placebo, but this was not statistically significant. 
Looking at health related quality of life (HRQoL) there was improvement in 5 of the 8 
domains of the short form 36 (SF-36) in patients receiving epratuzumab. These 
improved domains were bodily pain, social function, role emotional, mental health 
and vitality (the largest improvement being seen in vitality) (46).  
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The incidence of adverse events (AE) and serious adverse events (SAEs) were 
similar between all groups and there were no unexpected findings of concern and 
likely to be due to trial medication in the epratuzumab exposed patients. There was 
one drug unrelated death in the 720mg/m2 group. The patient died of cerebral 
haemorrhage 16 weeks after the last dose. Of the 51 patients receiving epratuzumab 
2 patients developed low level titres of human anti-human antibody (HAHA). 
Immunological studies showed a medium B-cell reduction of 31% and 52% from 
baseline in the 360mg/m2 and 720mg/m2 groups respectively. There were no 
changes in T cell numbers and immunoglobulin levels.  
 
The limitations of this study are that due to early discontinuation the study was 
underpowered for the primary end point. Due to the relatively small numbers and as 
the exploratory analysis was not adjusted for multiple testing the results should be 
interpreted with caution. Overall the study points to some efficacy of epratuzumab on 
disease severity, corticosteroid sparing and HRQoL improvements and no concerns 
with drug safety.  
 
4.3 ALLEVIATE open label extension trial (SL0006) (45,46)    
 
ALLEVIATE patients at US sites were eligible for enrolment into the open label 
extension (SL0006) if they had benefitted from treatment in the randomised 
controlled trial and there were no safety concerns related to the administration of 
epratuzumab. The main objective was to assess the long-term safety and efficacy of 
an epratuzumab 360mg/m2 maintenance regime of 12-week cycles (2 infusions on 
weeks 0 and 1 of each cycle). BILAG disease activity was assessed at 4 weekly 
intervals and 29 patients were recruited but 4 patients discontinued the study 
prematurely, 1 due to lack of efficacy and 3 due to SAEs.  
 
There was a reduction in mean total BILAG score of 8.4 at entry to 7.2 at week 100. 
No new or unexpected AEs, SAEs or infections were reported. All 29 patients 
reported at least 1 AE with SAEs occurring in 10 patients. Corticosteroid sparing 
effects were observed with 77.9% of patients having reductions in corticosteroid 
dose and 40.7% stopping corticosteroids altogether. Improvement in HRQoL from 
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the ALLEVIATE baseline were maintained or improved in all SF-36 domains during 
SL0006.  
 
4.4 Phase IIb trial: EMBLEM (47)     
 
EMBLEM was a 12 week dose and regimen finding phase IIb, multicentre, 
multinational randomised controlled trial investigating the efficacy and safety of 
various epratuzumab doses in moderate to severe SLE. Inclusion and exclusion 
criteria are summarised in table 3 and the results in table 4. Inclusion criteria were 
similar to the ALLEVIATE studies with the addition of patients having to have a 
SLEDAI-2K total score of ≥ 6.  
 
Patients were randomised to placebo or epratuzumab at the doses; 200mg 
cumulative dose (cd) (100mg every other week (EOW)), 800mg cd (400mg EOW), 
2400mg cd (600mg weekly), 2400mg cd (1200mg EOW) and 3600mg cd (1800mg 
EOW) at a 1:1:1:1:1:1 ratio. Patients were given infusions between weeks 0 and 3. 
Clinically efficacy was assessed at weeks 4, 8 and 12. 
 
The primary endpoint was the BICLA responder rate at week 12 according to this 
composite endpoint (14). In the study protocol steroids could be tapered at discretion 
of investigators. The study had multiple secondary endpoints looking at responder 
rate at 8 weeks, the individual disease severity scores at various time-points and 
corticosteroid usage. Various immunological parameters were also looked at as well 
as drug safety.  
 
In total 227 patients underwent randomisation. Baseline characteristics were similar. 
Premature discontinuation occurred in 28 patients, most commonly due to lack of 
efficacy. The study failed to meet its primary outcome, with responder rates between 
all epratuzumab groups combined and placebo not being significant. In an 
exploratory paired analysis there was a statistically significant difference in 
responders in the epratuzumab 2400mg cd (600mg weekly), 2400mg cd (1200mg 
every other week) and combined 2400mg cd groups (p values 0.03, 0.07 and 0.02 
versus placebo respectively) compared to placebo.  
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Looking at secondary outcomes there was no statistically significant difference in 
response rates between placebo and epratuzumab groups at weeks 8 and 12. 
Corticosteroid dose changes at week 12 compared to baseline were minimal. 
 
In a post hoc exploratory analysis the epratuzumab 2400mg cd (600mg weekly) 
group had reductions in musculoskeletal, mucocutaneous, cardio-respiratory, 
neuropsychiatric, constitutional and renal BILAG systems compared to placebo. The 
epratuzumab 2400mg cd (1200mg EOW) showed BILAG system improvement in 
musculoskeletal, mucocutaneous and neuropsychiatric scores compared to placebo.  
 
Laboratory studies showed that immunoglobulin levels stayed within normal limits. 
There was a moderate reduction in B-cell counts and CD22 expression in patients 
who received epratuzumab. The were no trends observed in complement and auto-
antibody levels. 
 
The EMBLEM study did not raise any new safety concerns. AEs and SAEs were 
similar across all groups and unrelated to epratuzumab dose. The most common 
AEs were headache, nausea, upper respiratory tract infection and urinary tract 
infection. There were no deaths. 
 
In summary EMBLEM showed no overall efficacy of epratuzumab in the primary 
outcome however exploratory analysis showed a statically significant improvement in 
both epratuzumab 2400mg cd groups compared to placebo. Hence these dosing 
regimens were used in the phase III studies. EMBLEM flagged no new safety signals 
and demonstrated that epratuzumab is generally well tolerated. EMBLEM was the 
first trial to use the BICLA composite endpoint (14).  
 
4.5 EMBLEM open label extension (SL0008) (48)   
 
Patients who completed the 12 weeks of the EMBLEM study or who discontinued 
due to lack of efficacy but completed ≥ 8 weeks of the trial where eligibly for 
enrolment into SL0008, the open label extension to EMBLEM. Patients received 12 
week treatment cycles of epratuzumab 1200mg infusions at weeks 0 and 2 (2400mg 
cd) plus SOC. The primary endpoint was safety of long term epratuzumab therapy. 
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Secondary outcomes included efficacy as defined by BILAG, SLEDAI-2k and PGA 
response as well as effect on HRQOL. Corticosteroid dosing during the study was 
analysed as well. 
 
In total 203 patients were entered into the study with 113 completing the study. 90 
(44.3%) patients discontinued the study with the most common reasons being AEs 
(14.3%) and lack of efficacy (11.3%). The study ran for 108 weeks in total.  
 
AEs were reported in 192 patients (94.6%) of which 51 (25.1%) had SAEs. The most 
common AE was infection (68.0%), mostly urinary tract and upper respiratory tract 
infections. The most frequent SAEs were; severe infections (6.9%) such as sepsis or 
gastroenteritis, SLE flare (3.4%) and lupus nephritis (2.0%). One patient died due to 
pericarditis and heart failure, unrelated to the drug 43 days after the first infusion.  
 
The percentage of patients with overall BILAG improvement without worsening 
compared to EMBLEM baseline increased from 34.5% at SL0008 entry to 63.8% at 
week 108. The proportion of responding patients was greatest in the patients 
previously given placebo in EMBLEM. Median BILAG and SLEDAI scores decreased 
at week 108 compared to the EMBLEM baseline. Mean PGA and PtGA score 
improved. In terms of HRQOL outcomes clinically meaningful improvements in SF-
36 scores were seen at week 48 and were maintained or improved further at week 
108. Corticosteroid sparing effects were observed with the median corticosteroid 
dosage reducing from 10.0mg/day (EMBLEM baseline and SL0008 entry) to 
5.0mg/day at week 108. One confounder in this study was the relatively high number 
of discontinuations due to lack of efficacy. This may have positively shewed the 
results contributing to BILAG response and corticosteroid reductions in this study. 
 
4.6 Japanese Phase I/II study (49)  
 
A Japanese phase I/II multicentre, double blinded, randomised controlled trial 
assessed the safety, pharmacodynamics and pharmacokinetics of epratuzumab in 
Japanese patients with moderate to severe SLE. The treatment groups were the 
same as the EMBLEM study but without the 1800mg EOW group. All patients in the 
placebo group and 13 of the 16 epratuzumab patients reported AEs, with 2 
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epratuzumab patient reporting SAEs but no significant safety concerns. The drug 
half life was found to be 13 days and the drug concentrations increased between the 
first and last infusions. Immunological analysis demonstrated CD22 downregulation 
with a mild to moderate reduction in B cell number.  
 
4.7 EMBODY 1 and EMBODY 2 (33)     
 
EMBODY 1 and EMBODY 2 were two phase III multicentre, multinational, 
randomised double blind placebo-controlled trials looking at epratuzumab in 
moderate to severe SLE. It aimed to address the efficacy and safety of repeat 
courses of epratuzumab using 2 different regimens every 12 weeks compared to 
placebo (46,47). Inclusion and exclusion criteria were similar to the EMBLEM study 
and are summarised in table 3 and the results in table 4.  
 
Patients were randomised to courses of placebo, epratuzumab 600mg weekly 
(2400mg cd) and epratuzumab 1200mg EOW (2400mg cd) in a 1:1:1 ratio. All 
infusions were given over a 4 week period at the start of each 12 week treatment 
cycle. A total of 4 cycles over 48 weeks were planned with assessments at weeks 0, 
4, 8, and 12 of each cycle. The protocol allowed corticosteroids to be increased up to 
25% from baseline without making the patient a non-responder up to week 8, 
corticosteroid reduction was encouraged but not mandated thereafter. Other 
immunosuppressant or anti-malarial medications had to be kept at baseline dose 
unless toxicity was suspected.  
 
The primary outcome was the responder rate at week 48 according to the composite 
BICLA endpoint. Secondary outcomes were BICLA response at weeks 12, 24 and 36 
as well as corticosteroid dose changes from baseline at weeks 24 and 48. HRQOF 
outcomes in the form of SF-36 and other patient reported outcomes were also 
measured.  
 
In total EMBODY 1 and EMBODY 2 randomised 793 and 791 patients respectively. 
Baseline demographics and disease activity between groups and studies were 
comparable. Unfortunately 265 (33.4%) and 258 (32.6%) patients prematurely 
discontinued EMBODY 1 and EMBODY 2 respectively. The most common cause for 
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premature discontinuation was lack of efficacy in all groups. One study site in 
EMBODY 1 was excluded due to protocol violations, these discontinuations were 
spread evenly across all treatment arms.  
 
Both studies failed to show a significant difference in the primary outcome. The 
BICLA response rates in EMBODY 1 were 34.1% in the placebo group, 39.8% in the 
1200mg EOW group and 37.5% in the 600mg weekly group. BICLA response rates 
in EMBODY 2 were 33.5% in the placebo group, 34.1% in the 1200mg EOW group 
and 35.2% in the 600mg weekly group. Both studies observed improvements in 
disease activity in both placebo and treatment groups within 12 weeks of starting 
therapy. Both studies showed a similar number of non-responders (due to no 
treatment response or disallowed changes in concomitant medications) in each 
treatment group. About one third of patients in total discontinued the study early 
before week 48. This was possibly due to a perceived lack of efficacy early and the 
desire to enter the open label extension for which patients were eligible to enter after 
week 16.  
 
The EMBODY studies also failed to show any significant difference in any of the 
planned secondary outcome measures. At weeks 24 and 48 a similar but relatively 
small proportion of patients from each treatment group had achieved reduction in 
corticosteroid dose (37.7-38.6% and 35.6-36.7% in EMBODY 1 and EMBODY 2 
respectively). There was no significant difference in BICLA responders at weeks 12, 
24 and 36. Overall there were similar improvements observed in overall BILAG-
2004, SLEDAI-2K, PGA, PtGA scores and HRQOL outcomes such as SF-36 and 
LupusQoL in all treatment groups. Additional analyses addressing geographic 
region, ethnicity, baseline medications and immunological parameters showed no 
significant differences. Post hoc analysis using an adjusted BICLA definition of 
response in which rules for disallowing changes in concomitant medications were 
disregarded also failed to show any significant differences.  
 
Immunological responses were comparable to the EMBLEM and ALLEVIATE studies 
with a medium reduction in peripheral B cells of 30-40% in patients who received 
epratuzumab confirming that the drug was biologically active.  Epratuzumab had no 
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effect on T cell, IgA and IgG levels, although a 20% decrease in IgM levels was 
observed.  
 
There were no new safety concerns. The incidence of adverse events was similar 
between all treatment groups. AEs occurred in 79.9-88.0% of all patients, the most 
common being infections (urinary tract and upper respiratory tract infections), 
headaches and nausea. SAEs occurred in 17.0-18.9% of patients, the most common 
being worsening of SLE. There were 5 and 4 deaths in EMBODY 1 and EMBODY 2 
respectively with 4 occurring in the placebo group and 5 occurring in patients 
receiving epratuzumab, consistent with previous 12 month lupus trials involving 
patients with moderate and severe disease activity at baseline. The causes of death 
ranged from pneumonia and septic shock to lupus myocarditis and pulmonary 
embolism.  
 
In summary EMBODY 1 and EMBODY 2 both failed to show differences in primary, 
secondary and exploratory outcomes. They also both showed a high placebo 
response rate, higher than had been seen in previous trials.  
 
5. Conclusion 
 
There have been a total of 7 clinical trials looking into the efficacy and safety of 
epratuzumab in SLE and 3 open label extension studies. Overall these trials 
demonstrate that epratuzumab is a well tolerated drug with similar AEs rates being 
reported in placebo and treatment groups. The most common AEs were simple 
infections such as urinary tract and upper respiratory tract infections as well as 
headaches, as reported in the normal population.  
 
All trials showed effects on B cells with peripheral B cell reductions of 30-50%. 
Complement levels and auto-antibody levels remain unchanged. Immunoglobulin 
levels tended to remain constant but the EMBODY trial reported a 20% reduction in 
IgM levels, although this was not associated with an increased risk of infection.  
 
Early trials, although not meeting their primary outcomes, showed promising 
outcomes with certain regimens and some potential corticosteroid sparing effects. 
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The EMBLEM trial showed a statistically significant increase in BICLA responders in 
the 2400mg cd (1200mg EOW or 600mg weekly) groups compared to placebo in a 
study with a low placebo response rate originally attributed to the use of this end-
point (47). The ALLEVIATE post hoc adjusted analysis demonstrated reasonable 
corticosteroid sparing effects of epratuzumab, with both OLE studies (SL0006 and 
SL0008) also showing corticosteroid sparing effects although the impact of non-
responders withdrawing may have biased the results (45,46,48). These promising 
results were not seen in the two EMBODY phase III RCTs, which showed no 
significant treatment effect of epratuzumab compared to placebo and no steroid 
sparing effects (33). This was a very disappointing result and it was not clear why the 
placebo response rate was higher than expected. It is possible that patients in trials 
take their regular medications (standard care immunosuppressants and anti-
malarials) for lupus more consistently than the before the trial as they have regular 
meetings with a dedicated clinical team. This could impact on the results by 
increasing the proportion in all groups that responded to conventional therapy, 
making it harder to discriminate the benefit of additional therapy with epratuzumab 
particularly in the context of corticosteroids that could be increased early in the trial 
and without the need to follow a strict protocol for steroid reduction. 
 
 
6. Expert commentary  
 
Epratuzumab has been a promising treatment option for lupus based on its effects 
on B cells and the attraction of modulating B cell function to reduce auto-immune 
disease without causing long term significant B cell depletion that might increase the 
risk of infection. Unfortunately none of the studies have shown very significant 
benefits and most importantly the two 48 week phase 3 EMBODY trials failed to 
meet planned primary and secondary end-points including reduction in disease 
activity, improvement in quality of life and corticosteroid sparing properties. The 
phase 2 trials and their open label extension studies had suggested that 
epratuzumab had the potential to achieve such end-points. 
 
Common to all of the controlled studies is the high placebo response rate which 
ranged from 21- 34.1%, and was highest in the 12 month EMBODY studies. The 
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reason for this high placebo response rate could be due to the intense amount of 
monitoring and regular interactions with expert lupus teams with far more study visits 
than an average patient would expect to attend clinic “in the real world”. As a result 
there may be more opportunity to optimise standard care, for example sunblock use 
and medication compliance, and hence explain the high placebo response rates. 
Patients continued corticosteroids and doses were increased at the start of the trials, 
potentially masking benefit from epratuzumab.  
 
None of the studies measured drug levels for conventional therapy such as 
hydroxychloroquine or mycophenolate but there have been reports of sub-optimal 
levels that increased during previous studies (4). This may be particularly relevant 
considering that some trial centres were in countries with insurance based health 
care systems and varying availability of specialists to some patients with lupus, such 
as USA and India. Therefore some of the patients entered into the trials will have got 
significantly more health care input, disease monitoring and regular prescriptions 
than before the trials, potentially increasing response to conventional medications, 
hence driving up the placebo response rates and response rates in all groups 
unrelated to trial medication. Therefore, even if epratuzumab has a mild to moderate 
disease ameliorating effect the high placebo response rates would have drowned 
this signal out. This phenomenon of intensive outpatient management with SOC 
causing improved outcomes has also been described in rheumatoid arthritis (50)  
and discussed in another review (51). The APRIL-SLE randomised controlled trial 
investigating the efficacy and safety of atacicept, a B-lymphocyte stimulator (BLyS) 
and A proliferation-inducing ligands (APRIL) antagonist, overcame this potential 
confounder by first giving all patients a standard regime of corticosteroids, then only 
randomising patients with inactive disease in response to steroids and standard of 
care (52). Hence ensuring that all patients had optimised standard of care before 
randomisation and accessing more effectively the ability for atacicept to prevent 
flares. This could be applied to future SLE trials to overcome these inconsistencies, 
but has the drawback of not testing the drugs ability to treat flares or its corticosteroid 
sparing effects.  
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Against this hypothesis were the high rates of early discontinuation due to inefficacy, 
but the opportunity to move to an open label trial may have encouraged patients to 
withdraw early (from week 16 onwards) in the EMBODY trials to secure 
epratuzumab. The rates of withdrawal in the open label studies were less clearly due 
to lack of or loss of efficacy than in EMBODY but nevertheless the numbers were 
significant (44% in EMBLEM extension SL0008; 14% related to efficacy). Some 
patients may have had disease activity and QoL assessments confounded by 
chronic damage and co-morbidities such as fibromyalgia which can be confused with 
active lupus disease except by the most experienced physicians caring for lupus 
patients. Although some training was provided, not all trial centres involved 
physicians with specialist lupus clinics and experience of disease assessment 
methodology. In retrospect it is hard to assess whether the main reasons for 
withdrawal in the open label studies were lack of efficacy for lupus, poor perceived 
health due to co-morbid conditions or withdrawal of consent to continue as improved 
or wanting to plan pregnancy.  
 
More patients might have continued with epratuzumab long term if the benefits from 
the regimen administered led to more consistent improvement in lupus facilitating 
more significant reductions in corticosteroids. There is a concern that the dosing 
regimen of epratuzumab was sub-optimal. The original dosing came from experience 
of epratuzumab in the treatment of lymphoma. The dosing regimen of 12 weekly 
cycles with 2 – 4 infusions between weeks 0 and 4 was arbitrary. Initial drug level 
measurements showed that epratuzumab was detectable at 4 weeks post last 
infusion (43). Given that the more recent assessment in the Japanese open label 
study (49) suggested that the half life of epratuzumab was 13 days and not 23 days 
as suggested in the original lymphoma studies (26, 42), perhaps the 12 weekly 
regimen was not optimal. The regimens used may have been sub-therapeutic for 
lupus although associated with some evidence of B cell modulation. In all the clinical 
trials the primary outcome time point was at the end of a 12 week cycle (ALLEVIATE 
1, 2 and EMBLEM at 12 weeks, EMBODY 1 and 2 at 48 weeks). There have been 
anecdotal, unsolicited and uncontrolled reports from patients in the open label 
studies that they derived benefit from the drug but that the effects only lasted 6-8 
weeks after each infusion course. Therefore by the time of assessment the drug 
levels may not have been optimal resulting in inability to document significant 
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improvement.  Most monoclonal antibodies given by IV infusion are administered on 
a 4-8 weekly basis. The possibility of administering epratuzumab more frequently to 
maintain higher drug levels has not been tested in lupus. The reduction in B cell 
numbers has been taken as evidence of biological efficacy but few studies 
addressing its other mechanisms of action on autoimmune disease (eg cytokines, 
cell migration etc) have been undertaken. Only very limited regimens were tested in 
the phase 2 studies, and additional studies looking at different regimens using 
different dosing and retreatment schedules might have been more successful than 
using the 12 week cycle regimen. 
 
Another disadvantage of these studies is that they have excluded patients with 
severe renal and neuropsychiatric disease as well as patients with anti-phospholipid 
syndrome that might have benefitted most from B cell modulation as they are less 
likely to respond promptly to conventional therapy with azathioprine, methotrexate, 
mycophenolate mofetil and anti-malarials (usually hydroxychloroquine). Such 
patients have derived benefit from rituximab in many open label studies of patients 
refractory to conventional therapy even though rituximab failed its phase 3 
randomised controlled trials (4).  
 
The possibility of other sub-groups of lupus patients responding to epratuzumab has 
been raised by recent post-hoc analyses of EMBODY. These have suggested that 
lupus patients that have anti-SSA (anti-Ro) antibodies and self-reported clinical sicca 
symptoms associated with Sjogren’s syndrome may benefit from epratuzumab as 
they show the best BICLA response rates (53). The post hoc analysis identified 112 
lupus patients with a diagnosis of Sjogren’s syndrome who were anti-SS-A positive, 
of which 40 had received placebo and 72 had received epratuzumab. A statistically 
significant higher BICLA response rate was seen at 24 weeks in patients receiving 
epratuzumab compared to placebo but there was a non-significant difference at 48 
weeks. Epratuzumab was well tolerated with no difference in the frequency of 
adverse effects between groups. It is important to emphasize that this analysis was 
post-hoc and aimed at hypothesis generation. It is unclear whether this is a potential 
subgroup that may benefit from epratuzumab or is just an artefact of post-hoc 
analysis, further prospective studies are needed to confirm this. There is no specific 
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mechanism as to why this subgroup may benefit and this is another reason why the 
finding should be interpreted with caution.  
 
The reason why epratuzumab has failed to show efficacy could be because CD22 is 
the wrong target. Rituximab and belimumab are the B cell therapies that have shown 
clinical efficacy (albeit with mixed results). Rituximab targets CD20, which is 
selectively expressed by pre-B and mature B cells. The main mechanism of action is 
through depletion of these subgroups secondary to ADCC and CDC. Belimumab on 
the other hand targets soluble B-lymphocyte stimulator (BLyS), a cytokine that is vital 
in B cell development, proliferation and survival (51). Both rituximab and belimumab 
result in substantial depletion of circulating B cells and normalisation of complement, 
unlike epratuzumab which works via immunomodulation and is associated with less 
B cell depletion. The results of the epratuzumab, rituximab and belimumab studies 
are reasonably comparable as the study designs were all very similar. The 
EXPLORER (rituximab) study (54), used classic BILAG as the outcome and the 
BLISS-52 and BLISS-76 (belimumab trials 19,20) used the SLE responder index 
(similar to the BICLA index – see table 2). One of the reasons why the rituximab 
studies failed to demonstrate efficacy was because for a patient to be a responder 
they were not allowed any new BILAG B grade disease. This meant that patients 
could improve in all systems but then develop a photosensitive rash due to failure to 
wear sun protection making them a non-responder, even if the rash was less severe 
than at baseline. For this reason the definition of a BILAG responder was changed in 
the belimumab and epratuzumab studies to allow 1 new BILAG B score and this is 
the major difference between the studies. The rituximab trials also used a lot of 
corticosteroids early in all patients, much more than most other studies, which may 
have reduced the ability to detect difference in outcomes between groups with 
relatively small numbers of patients compared with the belimumab trials (19,20). 
 
Further work is looking at combining biological therapies in SLE. A current trial is 
investigating the combination of rituximab followed by belimumab in the treatment of 
lupus. This is based on the observation that after rituximab mediated depletion of B 
cells there is a peak in soluble BLyS (55). Epratuzumab has been used in 
combination with rituximab in the treatment of non-Hodgkin’s lymphoma showing 
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both efficacy and safety (56). Epratuzumab might have a role in combined biological 
therapy for SLE as well.   
 
The other possibility is that B cells are the wrong target. Type 1 interferons and the 
co-stimulation pathways; inducible T-cell co-stimulator (ICOS), CD40 and TNF-like 
weak inducer of apoptosis (TWEAK) are all promising potential targets some of 
which are subject to ongoing clinical trials (51). 
 
7. Five year view 
 
The likelihood of there being another clinical trial for epratuzumab in SLE soon is 
unlikely with UCB terminating its collaboration with Immunomedics for the 
development of epratuzumab for autoimmune disease (57). However a recent post 
hoc analysis of the EMBODY trials has demonstrated possible efficacy of 
epratuzumab in anti-SSA positive patients with lupus and features of Sjögren’s 
Syndrome (53). An earlier open label phase I/II study looking at epratuzumab in 
primary Sjögren’s syndrome demonstrated some efficacy and drug safety (58). The 
primary endpoint in this study was a composite endpoint of Schirmer’s test, fatigue, 
whole salivary flow and erythrocyte sedimentation rate (ESR). This could potentially 
open the door for further trials investigating the role of epratuzumab in the 
management of Sjogren’s syndrome and the subgroup of patients with SLE and 
Sjogren’s syndrome in whom B cell modulation by epratuzumab may be most 
effective. There is also ongoing clinical research looking into the use of epratuzumab 
in follicular lymphoma and acute lymphoblastic leukaemia, however this is beyond 
the scope of this review.  
 
Key Issues  
 
• The pathogenesis of SLE is primarily thought to be B cell mediated  
• Disease activity in SLE is measured using the disease activity indices BILAG-
2004 and SLEDAI-2K and the composite end-point BICLA includes these, 
PGA and no need for additional immunosuppressive treatment 
• Epratuzumab is a humanized CD22 targeted IgG1 monoclonal antibody 
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• Epratuzumab works by activation of CD22 with causes immunomodulation of 
B cells via changes in surface receptor expression, cytokine expression, 
reduction in plasma cell generation and effects on cell adhesion and migration 
• It has B cell specificity, reducing peripheral B cell count by 30-50% without 
having major effect on immunoglobulin levels or other parts of the immune 
system  
• Epratuzumab has good tolerability and safety profiles 
• All randomised controlled trials have failed to show a significant difference in 
primary endpoints between epratuzumab and placebo groups using 12 week 
cycles of epratuzumab 
• It is not clear why trials have failed to demonstrate efficacy but high placebo 
response rates from optimisation of standard of care and sub-optimal dosing 
regimen may have played a role  
• Post-hoc analysis of the EMBODY phase III RCT highlighted patients with 
anti-SSA and Sjogren’s syndrome as a possible subgroup of SLE patients 
who may benefit from epratuzumab, so further research is needed to explore 
this and other potential sub-groups that might respond. 
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Figure 1 legend 
Immunomodulatory mechanisms of epratuzumab. Epratuzumab dependent down 
regulation of the adhesion molecules CD62L and β7 integrin inhibiting 
recruitment of B cells to inflamed tissue. Epratuzumab dependent internalisation 
of CD22 and of CD79α resulting in reduced BCR signalling. Epratuzumab 
dependent down regulation of CD19, CD79β and CD21 via trogocytosis, resulting 
in reduced BCR signalling. Epratuzumab dependent inhibition of the pro-
inflammatory cytokines TNF and IL-6 whilst preserving the anti-inflammatory 
cytokine IL-10. 
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